DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Ubicación actual:
> This Story

Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment



Molecular Imaging Homepage

CereMetrix Silver neuroimaging analytics platform scores FDA approval Quantifies brain function down to the voxel level

New PET imaging agent predicts tumor response to lung cancer drug Could lead to better patient management and outcomes

PET beats SPECT for detecting coronary artery disease: study Detected 79 percent of severe obstructive cases versus 70 percent

PET/MR and the future of pediatric chemotherapy Dr. Ashok Joseph Theruvath, postdoctoral research fellow in the Molecular Imaging Program at the Stanford School of Medicine discusses promising research for assessing pediatric chemo outcomes

Availity announces debut of pre-clearance service at HIMSS Confirms imaging authorization in minutes and ensures patient payments prior to visit

NTP Radioisotopes facility resumes production following hydrogen leak Produces Mo-99 for US, European and other global customers

NCCN adds Axumin to guidelines for prostate cancer treatment Enhances support for imaging agent from private payors

Lisa Hazen ARRT appoints new Nuclear Medicine Technology (NMT) Relationship Manager

SHINE completes Building One of medical isotope production facility Facility is projected to become domestic source for Mo-99 production in US

Ian Wilson ImaginAb appoints chief operating officer

UAlberta researchers in the lab

Two new imaging agents may help physicians make better and quicker treatment decisions

por Lauren Dubinsky , Senior Reporter
Two new imaging agents may help physicians personalize cancer therapy and determine a patient's response to a drug 24 hours after it's administered.

These imaging agents can be used with PET and fluorescence imaging to visualize the formation of tumor-associated blood vessels and track tumor growth.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Researchers at the University of Alberta in Canada worked with colleagues at Western University and Case Western Reserve University to develop the imaging agents. They investigated a protein called EGFL7 that is specific to actively growing blood vessels.

The team started by creating peptides that attach to EGFL7 proteins in order to determine if they would be useful for imaging applications. PET exams using the peptide were performed on mice with tumors in order to localize the tumors and illuminate them.

They also used the peptide to create nanoparticles and those were shown to accumulate in the new blood vessels and illuminate as well.

Many cancer drugs on the market inhibit the formation of new tumor-related blood vessels, but it's difficult to determine which patients would benefit from them. They can be toxic for one patient and lifesaving for another.

The team believes that these new imaging agents can provide physicians with the information they need to make more personalized treatment decisions.

The agent can be used prior to treatment in order to see how many blood vessels are forming. That would determine whether an individual patient is a candidate for those drugs.

The agents can also be used during treatment to monitor their response to therapy. Traditionally, physicians measure changes in tumor size up to a month after treatment, but this new method could determine that in 24 hours.

The next step is to test the imaging agents in a treatment setting. The researchers will initially perform experiments on animal models and then move on to clinical work.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2018, Inc.